or Try an Advanced Search...

    Petach Stocks List

    Symbol Grade Name % Change
    PYPD F PolyPid Ltd. 0.00
    CYBR D CyberArk Software Ltd. 0.04
    ELTK F Eltek Ltd. 0.29
    CANF F Can-Fite Biopharma Ltd Sponsored ADR (Israel) 0.48
    TEVA B Teva Pharmaceutical Industries 2.52
    View As Page of Charts
    Related Industries: Biotechnology Contract Manufacturers Drug Manufacturers - Specialty & Generic Software - Infrastructure
    Related Stock Lists: Cancer Immunosuppressants Medicine Active Pharmaceutical Ingredients Aerospace Allergy Antibiotics Arthritis Asthma Biotechnology Biotie Therapies Birth Control Blood Cells Bone Bone Grafting Bronchial Asthma Carcinoma Chemical Entities Cholesterol Chronic Lymphocytic Leukemia

    Related ETFs - A few ETFs which own one or more of the above listed Petach stocks.

    Symbol Grade Name Weight
    ISRA D Market Vectors Israel ETF 15.31
    EIS D iShares MSCI Israel Capped Investable Market Index Fund 14.21
    ITEQ D BlueStar TA-BIGITech Israel Technology ETF 8.27
    PSWD F Xtrackers Cybersecurity Select Equity ETF 5.08
    BUG D Global X Cybersecurity ETF 4.88
    View all Petach ETFs...
    Compare ETFs
    Compare EIS to BUG Compare EIS to ITEQ Compare ISRA to EIS

        Petach Stocks Recent News

        Date Stock Title
        May 13 CANF Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study
        May 12 TEVA These 10 Large Cap Stocks Shined Brightest Last Week (May 5-May 11, 2024): Are They In Your Portfolio?
        May 10 CANF Can-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
        May 10 CANF Can-Fite receives FDA IND clearance for Phase IIb MASH treatment trial
        May 9 TEVA TEVA Q1 Earnings Miss, Schizophrenia Study Meets Goal, Stock Up
        May 9 CYBR CyberArk Previews IMPACT 24: The Identity Security Conference
        May 9 TEVA Teva Pharmaceutical Industries Limited (NYSE:TEVA) Q1 2024 Earnings Call Transcript
        May 9 TEVA Affirm stock sinking, Good Buy or Goodbye: Market Domination
        May 9 CANF Can-Fite stock up on FDA IND clearance for namodenoson to treat MASH patients in mid-stage study
        May 9 TEVA Teva Pharmaceutical Industries First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
        May 9 TEVA Teva Pharmaceutical: 6 Takeaways From Q1 2024 Earnings Results
        May 9 CANF Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study
        May 9 TEVA Teva and Medincell report positive data for TEV-‘749 in schizophrenia trial
        May 9 TEVA Teva: Sustained Revenue Growth Amid Financial Strain (Rating Downgrade)
        May 8 TEVA Teva Pharmaceutical Industries (TEVA) Q1 2024 Earnings Call Transcript
        May 8 TEVA Teva Pharmaceutical Industries Limited (TEVA) Q1 2024 Earnings Call Transcript
        May 8 TEVA Teva hits a five-year high on schizophrenia trial win, Q1 beat
        May 8 TEVA Teva Pharmaceutical Industries (TEVA) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
        May 8 TEVA Teva Surges To 5-Year High On Maintained Outlook Despite Mixed First Quarter
        May 8 TEVA Teva Pharmaceutical Industries Limited 2024 Q1 - Results - Earnings Call Presentation
        Related Industries: Biotechnology Contract Manufacturers Drug Manufacturers - Specialty & Generic Software - Infrastructure
        Related Stock Lists: Cancer Immunosuppressants Medicine Active Pharmaceutical Ingredients Aerospace Allergy Antibiotics Arthritis Asthma Biotechnology Biotie Therapies Birth Control Blood Cells Bone Bone Grafting Bronchial Asthma Carcinoma Chemical Entities Cholesterol Chronic Lymphocytic Leukemia
        Petach

        Browse All Tags